Objective: In this research, the influence of the initial endothelial activation and stress index (EASIX) on the prognosis of patients with metastatic renal cell carcinoma (mRCC) undergoing first-line treatment with tyrosine kinase inhibitors (TKIs) was examined.Methods: This study, conducted retrospectively at a single center, included patients with mRCC who received first-line TKI therapy. The EASIX score was determined from serum lactate dehydrogenase, creatinine, and platelet count measurements taken within 15 days before starting treatment. Patients were divided into low and high EASIX groups according to the cohort’s median score. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.Results: A total of 99 patients were included in the study. The median PFS was 11.5 months, while the median OS was 34.3 months. Those with elevated EASIX scores had notably reduced PFS and OS, with PFS at 8.6 months compared to 19.1 months (P < .001) and OS at 24.8 months versus 61.9 months (P = .003). In multivariate analyses, high EASIX remained an independent predictor of shorter PFS (hazard ratio [HR] = 2.77, 95% CI: 1.60-4.79; P < .001) and OS (HR = 2.53, 95% CI: 1.32-4.84; P = .005).Conclusion: Baseline EASIX was independently associated with survival outcomes in patients with mRCC undergoing first-line TKI treatment. As a simple and readily accessible biomarker, EASIX may provide addi-tional prognostic information beyond conventional risk models. Prospective validation is warranted, par-ticularly in the context of contemporary treatment strategies.Keywords:
Objective: In this research, the influence of the initial endothelial activation and stress index (EASIX) on the prognosis of patients with metastatic renal cell carcinoma (mRCC) undergoing first-line treatment with tyrosine kinase inhibitors (TKIs) was examined.Methods: This study, conducted retrospectively at a single center, included patients with mRCC who received first-line TKI therapy. The EASIX score was determined from serum lactate dehydrogenase, creatinine, and platelet count measurements taken within 15 days before starting treatment. Patients were divided into low and high EASIX groups according to the cohort’s median score. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.Results: A total of 99 patients were included in the study. The median PFS was 11.5 months, while the median OS was 34.3 months. Those with elevated EASIX scores had notably reduced PFS and OS, with PFS at 8.6 months compared to 19.1 months (P < .001) and OS at 24.8 months versus 61.9 months (P = .003). In multivariate analyses, high EASIX remained an independent predictor of shorter PFS (hazard ratio [HR] = 2.77, 95% CI: 1.60-4.79; P < .001) and OS (HR = 2.53, 95% CI: 1.32-4.84; P = .005).Conclusion: Baseline EASIX was independently associated with survival outcomes in patients with mRCC undergoing first-line TKI treatment. As a simple and readily accessible biomarker, EASIX may provide addi-tional prognostic information beyond conventional risk models. Prospective validation is warranted, par-ticularly in the context of contemporary treatment strategies.Keywords:
Objective: In this research, the influence of the initial endothelial activation and stress index (EASIX) on the prognosis of patients with metastatic renal cell carcinoma (mRCC) undergoing first-line treatment with tyrosine kinase inhibitors (TKIs) was examined.Methods: This study, conducted retrospectively at a single center, included patients with mRCC who received first-line TKI therapy. The EASIX score was determined from serum lactate dehydrogenase, creatinine, and platelet count measurements taken within 15 days before starting treatment. Patients were divided into low and high EASIX groups according to the cohort’s median score. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.Results: A total of 99 patients were included in the study. The median PFS was 11.5 months, while the median OS was 34.3 months. Those with elevated EASIX scores had notably reduced PFS and OS, with PFS at 8.6 months compared to 19.1 months (P < .001) and OS at 24.8 months versus 61.9 months (P = .003). In multivariate analyses, high EASIX remained an independent predictor of shorter PFS (hazard ratio [HR] = 2.77, 95% CI: 1.60-4.79; P < .001) and OS (HR = 2.53, 95% CI: 1.32-4.84; P = .005).Conclusion: Baseline EASIX was independently associated with survival outcomes in patients with mRCC undergoing first-line TKI treatment. As a simple and readily accessible biomarker, EASIX may provide addi-tional prognostic information beyond conventional risk models. Prospective validation is warranted, par-ticularly in the context of contemporary treatment strategies
Objective: In this research, the influence of the initial endothelial activation and stress index (EASIX) on the prognosis of patients with metastatic renal cell carcinoma (mRCC) undergoing first-line treatment with tyrosine kinase inhibitors (TKIs) was examined.Methods: This study, conducted retrospectively at a single center, included patients with mRCC who received first-line TKI therapy. The EASIX score was determined from serum lactate dehydrogenase, creatinine, and platelet count measurements taken within 15 days before starting treatment. Patients were divided into low and high EASIX groups according to the cohort’s median score. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.Results: A total of 99 patients were included in the study. The median PFS was 11.5 months, while the median OS was 34.3 months. Those with elevated EASIX scores had notably reduced PFS and OS, with PFS at 8.6 months compared to 19.1 months (P < .001) and OS at 24.8 months versus 61.9 months (P = .003). In multivariate analyses, high EASIX remained an independent predictor of shorter PFS (hazard ratio [HR] = 2.77, 95% CI: 1.60-4.79; P < .001) and OS (HR = 2.53, 95% CI: 1.32-4.84; P = .005).Conclusion: Baseline EASIX was independently associated with survival outcomes in patients with mRCC undergoing first-line TKI treatment. As a simple and readily accessible biomarker, EASIX may provide addi-tional prognostic information beyond conventional risk models. Prospective validation is warranted, par-ticularly in the context of contemporary treatment strategies.Keywords:
Objective: In this research, the influence of the initial endothelial activation and stress index (EASIX) on the prognosis of patients with metastatic renal cell carcinoma (mRCC) undergoing first-line treatment with tyrosine kinase inhibitors (TKIs) was examined.Methods: This study, conducted retrospectively at a single center, included patients with mRCC who received first-line TKI therapy. The EASIX score was determined from serum lactate dehydrogenase, creatinine, and platelet count measurements taken within 15 days before starting treatment. Patients were divided into low and high EASIX groups according to the cohort’s median score. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.Results: A total of 99 patients were included in the study. The median PFS was 11.5 months, while the median OS was 34.3 months. Those with elevated EASIX scores had notably reduced PFS and OS, with PFS at 8.6 months compared to 19.1 months (P < .001) and OS at 24.8 months versus 61.9 months (P = .003). In multivariate analyses, high EASIX remained an independent predictor of shorter PFS (hazard ratio [HR] = 2.77, 95% CI: 1.60-4.79; P < .001) and OS (HR = 2.53, 95% CI: 1.32-4.84; P = .005).Conclusion: Baseline EASIX was independently associated with survival outcomes in patients with mRCC undergoing first-line TKI treatment. As a simple and readily accessible biomarker, EASIX may provide addi-tional prognostic information beyond conventional risk models. Prospective validation is warranted, par-ticularly in the context of contemporary treatment strategies.Keywords:
Objective: In this research, the influence of the initial endothelial activation and stress index (EASIX) on the prognosis of patients with metastatic renal cell carcinoma (mRCC) undergoing first-line treatment with tyrosine kinase inhibitors (TKIs) was examined.Methods: This study, conducted retrospectively at a single center, included patients with mRCC who received first-line TKI therapy. The EASIX score was determined from serum lactate dehydrogenase, creatinine, and platelet count measurements taken within 15 days before starting treatment. Patients were divided into low and high EASIX groups according to the cohort’s median score. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.Results: A total of 99 patients were included in the study. The median PFS was 11.5 months, while the median OS was 34.3 months. Those with elevated EASIX scores had notably reduced PFS and OS, with PFS at 8.6 months compared to 19.1 months (P < .001) and OS at 24.8 months versus 61.9 months (P = .003). In multivariate analyses, high EASIX remained an independent predictor of shorter PFS (hazard ratio [HR] = 2.77, 95% CI: 1.60-4.79; P < .001) and OS (HR = 2.53, 95% CI: 1.32-4.84; P = .005).Conclusion: Baseline EASIX was independently associated with survival outcomes in patients with mRCC undergoing first-line TKI treatment. As a simple and readily accessible biomarker, EASIX may provide addi-tional prognostic information beyond conventional risk models. Prospective validation is warranted, par-ticularly in the context of contemporary treatment strategies
